Approved For Release 2003/09/16
in 1)
TO: File
FROM: H. E. Puthoff, Ph.D.
SUBJECT: Policy Statement
DATE: 19 June 1978
LOCATION: 44
cc
In response to requests for information with regard to the psychic
research program at SRI International, this memo is to state for the
record that this program does not involve the use of hypnosis, drugs,
or other psychopharmacological agents, or treatment of research subjects
by subliminal technologies or other means of st.imulation unknown to them.
This policy statement derives from a broader SRI policy statement
concerning requirements governing activities with human subjects (SRI
International Administration Manual, Topic 812, Complete Revision
2 May 1977). This policy statement applies to all uses of human
subjects at or under the sponsorship of SRI International. It is
intended to comply with Department of Health, Education and Welfare
(DHEW) rules and regulations for the protection of human subjects, and
is concerned with the protection of any individual who may be at risk
as a consequence of participation as a subject in an experimental
activity. An individual is considered,to be at risk if he or she "may
be exposed to the possibility of injury, including physical, psychological,
or social injury, as a consequence of participation as a subject in any
research, development, or related activity which departs from the
application of those established and accepted methods necessary to meet
his needs, or which increases the ordinary risks of daily life, including
the recognized risks inherent in a chosen occupation or field of service."'
A Human Subjects Committee appointed by the Vice President and Chairman,,
office of Research Operations, SRI International, is responsible for
the enforcement of this policy.
SRI adheres to the statement of principles issued by the World
Medical Association, 10 Columbus Circle, New York, New York 10019, and
known as the Declaration of Helsinki. Copies are available from the
Chair-An of the SRI Human Subjects Committee.
1
Title 45 Code of Federal Regulations, Part 46.
CIA-RDP96-0071.41@01 100440001-2
Approved For Release 2003/09/16 : CIA-RDP96-00788RO01 100440001-2